IQVIA partners with Medera to advance cardiac gene therapy development

• IQVIA entered a strategic collaboration with Medera to speed development of cardiac gene therapies, using IQVIA’s global clinical trial and commercialization platform.
• IQVIA will support Medera’s FDA-cleared, first-in-human AAV gene therapy programs with regulatory filings, trial execution, patient recruitment, data quality.
• Partnership also expands use of Medera’s Novoheart mini-Heart human cardiac tissue platform for drug discovery, safety testing, reduced reliance on animal models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IQVIA Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804228708) on August 04, 2026, and is solely responsible for the information contained therein.